Last reviewed · How we verify
Varinecline (Chantix)
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking.
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking. Used for Smoking cessation.
At a glance
| Generic name | Varinecline (Chantix) |
|---|---|
| Sponsor | American University of Beirut Medical Center |
| Drug class | Nicotinic receptor partial agonist |
| Target | Alpha-4 beta-2 nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Varenicline binds with high affinity and selectivity to the alpha-4 beta-2 nicotinic receptor in the brain. As a partial agonist, it provides modest dopamine release to reduce withdrawal symptoms while simultaneously blocking nicotine from binding to these receptors, preventing the reinforcing effects of smoking and reducing the urge to smoke.
Approved indications
- Smoking cessation
Common side effects
- Nausea
- Insomnia
- Abnormal dreams
- Headache
- Dizziness
- Constipation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varinecline (Chantix) CI brief — competitive landscape report
- Varinecline (Chantix) updates RSS · CI watch RSS
- American University of Beirut Medical Center portfolio CI